CagriSema vs Wegovy: Complete Comparison Guide

CagriSema vs Wegovy: Complete Comparison Guide

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Weight loss medications require a prescription and ongoing medical supervision. Discuss all treatment decisions with your healthcare provider, who can evaluate your individual health history, medications, and goals.

April 2026 context: CagriSema NDA filed December 2025 — FDA decision expected Q4 2026. Orforglipron PDUFA date April 10, 2026 — not yet approved. Medicare Bridge for obesity GLP-1s pending Congressional action.

CagriSema is essentially Wegovy plus an amylin analog — and the clinical data shows that "plus" translates to roughly 5 additional percentage points of body weight loss. That is the core of this comparison.

Both medications are made by Novo Nordisk. Both contain semaglutide 2.4mg. But CagriSema adds cagrilintide 2.4mg, a long-acting amylin analog that targets a separate appetite-suppression pathway. The result, based on the REDEFINE trial program, is approximately 22% total body weight loss at 68 weeks — compared to 15-17% with standard Wegovy, or roughly 20.7% with the newer Wegovy HD (semaglutide 7.2mg).

There is a critical caveat: CagriSema is not yet FDA approved. As of April 2026, the NDA was filed just three months ago in December 2025, with no PDUFA date publicly disclosed. A decision is expected in late 2026 or 2027, but the timing remains genuinely uncertain. Wegovy (both standard and HD) is available today.

This guide compares the two medications across every dimension that matters — mechanism, clinical data, side effects, dosing, cost, and availability — so you can plan ahead with your provider. For a deeper look at CagriSema alone, see our CagriSema patient guide. For details on the higher-dose Wegovy option, see our Wegovy HD guide.

Quick Comparison Table: CagriSema vs Wegovy

Factor	CagriSema (Novo Nordisk)	Wegovy (Novo Nordisk)
Generic name	Cagrilintide 2.4mg + semaglutide 2.4mg	Semaglutide 2.4mg (standard) / 7.2mg (HD)
Mechanism	GLP-1 + amylin analog (dual pathway)	GLP-1 receptor agonist (single pathway)
Key trials	REDEFINE program (1-4)	STEP program (1-5), SELECT
Weight loss	~22% at 68 weeks (REDEFINE-1)	15-17% at 68 weeks (STEP-1); ~20.7% (Wegovy HD)
Administration	Weekly subcutaneous injection	Weekly subcutaneous injection (or oral tablet)
Titration	5 steps over 16 weeks	6 steps over 16 weeks
FDA status	NDA filed Dec 2025; under review, decision expected late 2026 or 2027	Approved June 2021
Availability	Not available	Available now (injectable and oral)
List price	TBD (expected premium over Wegovy)	$1,349/mo list
Typical out-of-pocket	TBD	$0-50/mo with insurance or Medicare Bridge
Oral option	No	Yes ($199-299/mo cash pay)
Common side effects	Nausea, diarrhea, vomiting, injection site reactions	Nausea, diarrhea, vomiting, constipation
Unique safety note	Injection site reactions (10-15%) from cagrilintide	Established long-term safety profile; cardiovascular benefit (SELECT trial)

How do CagriSema and Wegovy work differently?

Both contain semaglutide 2.4mg, but CagriSema adds cagrilintide 2.4mg — a long-acting amylin analog that suppresses appetite through a second, GLP-1-independent brain pathway. That stacking of two mechanisms is why CagriSema produces more weight loss (~22% vs ~15-17%).

Understanding the biological difference between these two medications explains why CagriSema produces more weight loss — and also why the improvement is incremental rather than transformative.

Wegovy: GLP-1 Receptor Agonist

Wegovy contains semaglutide, a synthetic version of the gut hormone GLP-1 (glucagon-like peptide-1). It works through several overlapping mechanisms:

• Appetite suppression. Semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase feelings of fullness. This is the primary driver of weight loss.
• Slower gastric emptying. Food moves through the stomach more slowly, keeping you feeling satisfied longer after meals.
• Blood sugar regulation. Semaglutide improves insulin secretion and reduces glucagon release, which benefits metabolic health independent of weight loss.
• Cardiovascular protection. The SELECT trial demonstrated a 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) in patients with obesity and established cardiovascular disease.

At the standard 2.4mg dose, semaglutide produces robust weight loss for most patients. But there is a ceiling to what a single-pathway approach can achieve. Some patients plateau before reaching their goals, and increasing the dose further (as with Wegovy HD at 7.2mg) produces diminishing returns with increasing side effects.

CagriSema: GLP-1 + Amylin Analog

CagriSema combines semaglutide 2.4mg with cagrilintide 2.4mg in a single weekly injection. You get everything Wegovy provides, plus an additional appetite-suppression mechanism.

Cagrilintide is a long-acting analog of amylin, a hormone naturally co-secreted with insulin by the pancreas after meals. Amylin acts on the area postrema and the hypothalamus — brain regions involved in satiety signaling — through pathways that are biologically distinct from GLP-1. In practical terms, it reduces food intake through a separate "channel" that GLP-1 does not fully engage.

The hypothesis behind CagriSema is straightforward: stacking two appetite-suppression pathways should produce more weight loss than either alone. The REDEFINE trial program confirmed this hypothesis — CagriSema consistently outperformed semaglutide alone.

A critical point: both Wegovy and CagriSema work primarily by reducing caloric intake. Neither meaningfully increases energy expenditure. The weight loss difference between them comes from cagrilintide adding a second brake on appetite.

What does the clinical trial data show for CagriSema vs Wegovy?

REDEFINE-1 showed CagriSema producing ~22% weight loss versus ~16% for the semaglutide 2.4mg arm — roughly 6 additional percentage points attributable to cagrilintide. STEP-1 showed standard Wegovy at 14.9%. CagriSema is the clear efficacy winner between these two, but Wegovy HD (semaglutide 7.2mg) at ~20.7% narrows the gap considerably.

The comparison between CagriSema and Wegovy rests on two major trial programs: REDEFINE (CagriSema) and STEP (Wegovy). The most informative data comes from trials where semaglutide served as a direct comparator.

REDEFINE-1: CagriSema vs Placebo

The flagship CagriSema trial enrolled adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. Key results at 68 weeks:

• CagriSema: ~22% mean total body weight loss
• Semaglutide 2.4mg (active comparator arm): ~16% mean weight loss
• Placebo: ~2% weight loss

CagriSema produced roughly 6 additional percentage points of weight loss compared to semaglutide alone — a clinically meaningful difference. Importantly, both the CagriSema and semaglutide arms used the same 2.4mg semaglutide dose, isolating the contribution of cagrilintide.

STEP-1: Wegovy vs Placebo (Reference)

The STEP-1 trial, which supported Wegovy's original approval, showed:

• Semaglutide 2.4mg (Wegovy): 14.9% mean weight loss at 68 weeks
• Placebo: 2.4% weight loss

Subsequent trials in the STEP program produced slightly varying results depending on the population studied, generally ranging from 15-17% weight loss at the standard 2.4mg dose.

Wegovy HD: Pushing Semaglutide Higher

Novo Nordisk's Wegovy HD (semaglutide 7.2mg) — a tripled dose — achieved approximately 20.7% weight loss in trials. This is relevant because it narrows the gap with CagriSema. The practical question for patients is whether CagriSema at 2.4mg + 2.4mg offers meaningful benefit over semaglutide at 7.2mg alone. The answer appears to be a modest 1-2 percentage point advantage for CagriSema, with a potentially different side effect profile. Whether that incremental benefit justifies a switch depends on individual circumstances.

For more on the higher-dose option, see our Wegovy HD semaglutide 7.2mg guide.

REDEFINE-4: CagriSema vs Tirzepatide (Context)

While not a direct Wegovy comparison, the REDEFINE-4 trial provides important context. CagriSema was tested head-to-head against tirzepatide (the active ingredient in Zepbound):

• CagriSema: 22.2% weight loss
• Tirzepatide: 25.3% weight loss

CagriSema missed the non-inferiority endpoint against tirzepatide. This positions CagriSema between Wegovy and Zepbound in terms of efficacy — better than semaglutide alone, but not as effective as tirzepatide. For a full breakdown, see our CagriSema vs Zepbound comparison.

What the Data Means in Practice

Here is how the weight loss landscape looks for a hypothetical 250-pound patient at roughly 68 weeks:

Medication	Expected Weight Loss (%)	Pounds Lost (250 lb patient)
Wegovy (semaglutide 2.4mg)	~15-17%	~38-43 lbs
Wegovy HD (semaglutide 7.2mg)	~20.7%	~52 lbs
CagriSema (cagrilintide + semaglutide 2.4mg)	~22%	~55 lbs
Zepbound (tirzepatide 15mg)	~22.5-25.3%	~56-63 lbs

CagriSema's advantage over standard Wegovy is substantial — roughly 12-17 additional pounds lost for a 250-pound patient. The advantage over Wegovy HD is smaller: approximately 3 pounds. Individual responses vary significantly, and some patients will respond better to one medication than another for reasons that remain poorly understood.

How do CagriSema and Wegovy compare on side effects?

Both medications share the same semaglutide-driven GI side effects (nausea, diarrhea, vomiting). CagriSema adds cagrilintide-specific injection site reactions (10-15% of patients) that Wegovy users won't experience. The overall GI profile is broadly similar.

Both medications share a common set of GI side effects because they both contain semaglutide. But CagriSema introduces amylin-specific effects that shift the side effect profile in notable ways.

Shared GI Side Effects

Both CagriSema and Wegovy commonly cause:

• Nausea — The most frequently reported side effect for both, typically worst during titration and improving over weeks 8-16.
• Diarrhea — Affects roughly 20-30% of patients on either medication.
• Vomiting — Reported by approximately 10-15% of patients in clinical trials.
• Constipation — More common with Wegovy as a standalone GLP-1; less frequently reported with CagriSema in trial data.

An interesting signal from the REDEFINE trials: CagriSema may produce somewhat lower rates of severe GI side effects compared to what you would expect from a GLP-1 at equivalent efficacy levels. The hypothesis is that cagrilintide provides additional appetite suppression without proportionally increasing GI disturbance, since amylin acts through different pathways than GLP-1. However, this observation requires confirmation in larger real-world populations. It is too early to claim CagriSema is "easier on the stomach."

For a detailed walkthrough of what to expect, see our CagriSema side effects guide.

CagriSema-Specific Side Effects

The cagrilintide component introduces effects not seen with Wegovy:

• Injection site reactions — Reported in 10-15% of CagriSema patients, significantly higher than with semaglutide alone. These include redness, swelling, itching, or hardening at the injection site. Most reactions are mild to moderate and resolve within days, but they are a notable source of discomfort that Wegovy patients do not experience.
• Potential amylin-related effects — Amylin analogs can cause nausea through mechanisms independent of GLP-1, though disentangling this from semaglutide-related nausea in clinical practice is difficult.

Wegovy-Specific Considerations

Wegovy has a longer real-world safety track record:

• Cardiovascular benefit — The SELECT trial provides reassuring data that semaglutide reduces cardiovascular risk. CagriSema has not been studied in a dedicated cardiovascular outcomes trial, though the semaglutide component would presumably confer similar benefits.
• Established safety profile — Over four years of post-marketing data, with well-characterized risks including pancreatitis (rare), gallbladder events, thyroid C-cell tumor risk (based on rodent studies, not confirmed in humans), and suicidal ideation (under ongoing monitoring with no conclusive signal).
• Oral formulation available — Oral Wegovy avoids injection site reactions entirely, which may matter for patients who are sensitive to injections.

Heart Rate Considerations

Both semaglutide and CagriSema have been associated with small increases in resting heart rate (typically 2-4 beats per minute). For CagriSema, the combination may produce a slightly larger effect. Clinical trial data has not identified this as a significant safety concern for most patients, but it warrants discussion with your provider if you have a history of cardiac arrhythmia.

How do CagriSema and Wegovy compare on dosing?

Both use once-weekly subcutaneous injections with ~16-week gradual titration schedules. CagriSema escalates both components simultaneously in a single pen; Wegovy escalates semaglutide alone. The practical experience is similar — one weekly injection, same titration timeline.

Both medications use a gradual titration schedule to minimize GI side effects, and both reach their maintenance dose in approximately the same timeframe.

Wegovy Dosing Schedule

Wegovy follows a 6-step titration over 16 weeks:

Weeks	Dose	Frequency
1-4	0.25mg	Weekly injection
5-8	0.5mg	Weekly injection
9-12	1.0mg	Weekly injection
13-16	1.7mg	Weekly injection
17+	2.4mg (maintenance)	Weekly injection

Patients who tolerate the 2.4mg dose and want additional efficacy may be titrated to Wegovy HD at 7.2mg, which adds further titration steps.

Oral Wegovy follows a different dosing protocol — see your provider for details on the oral formulation.

CagriSema Dosing Schedule

Based on clinical trial protocols, CagriSema uses a 5-step titration over 16 weeks, adjusting both the cagrilintide and semaglutide components simultaneously:

Weeks	Cagrilintide Dose	Semaglutide Dose	Frequency
1-4	0.25mg	0.25mg	Weekly injection
5-8	0.5mg	0.5mg	Weekly injection
9-12	1.0mg	1.0mg	Weekly injection
13-16	1.7mg	1.7mg	Weekly injection
17+	2.4mg	2.4mg (maintenance)	Weekly injection

Both doses escalate together in a single pen device. This means a single weekly injection, the same frequency as Wegovy. The convenience is comparable.

For a complete walkthrough of the expected titration process, see our CagriSema dosing guide.

Practical Dosing Notes

• Same injection frequency. Both are once-weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm.
• CagriSema is one injection for two drugs. Unlike some combination therapies that require separate injections, CagriSema delivers cagrilintide and semaglutide together from a single pen.
• Titration flexibility. With Wegovy, your provider can adjust the dose (including stepping down temporarily) if you experience intolerable side effects. Whether CagriSema's fixed-ratio combination allows the same flexibility in practice remains to be seen once it reaches market. The inability to independently adjust the two components could be a limitation for some patients.

How do CagriSema and Wegovy compare on price and availability?

Wegovy is available now at $1,349/month list price, with $0-50/month for many insured patients and an oral option at $199-299/month cash pay. CagriSema has no price and no approval — and will almost certainly cost more than Wegovy when it arrives. For patients asking "cheapest way to get semaglutide online," Wegovy (or its oral form) is the answer today; CagriSema is not yet an option.

This is where the comparison becomes most asymmetric. Wegovy is available today with established pricing and insurance pathways. CagriSema is not.

Wegovy: Available Now

• List price: $1,349/month
• With commercial insurance: $0-25/month for many patients with coverage; savings card available
• Medicare: ~$50/month expected under the Medicare GLP-1 Bridge program (scheduled to launch July 1, 2026 — not yet live as of April 2026)
• Cash pay (injectable): $1,349/month without insurance or savings programs
• Oral Wegovy: $199-299/month at cash-pay telehealth providers, providing an affordable entry point for patients without insurance coverage for weight loss medications
• Supply: Stable as of early 2026, following the supply constraints of 2023-2024

CagriSema: Pending Approval

• List price: Not announced. As a next-generation Novo Nordisk obesity medication, CagriSema is expected to be priced at a premium to Wegovy. Analyst estimates range from $1,300-1,600/month, though Novo Nordisk may pursue various pricing strategies depending on the competitive landscape at launch.
• Insurance coverage: Unknown. Insurers will need to establish coverage policies, which typically takes 3-6 months after FDA approval. Payers may require step therapy (trying Wegovy first) before covering CagriSema.
• Medicare: Coverage terms will depend on CMS policies at the time of approval.
• Cash pay: No cash-pay pricing has been established. There is no oral formulation of CagriSema under development, so the affordable oral pathway available with Wegovy will not exist for CagriSema.
• Supply: Novo Nordisk has not disclosed manufacturing capacity for CagriSema. Given the company's history of supply constraints with Wegovy and Ozempic, initial availability may be limited.

The bottom line on pricing: CagriSema will almost certainly cost more than Wegovy, and it will take months after approval before insurance pathways and savings programs are fully established. Patients who need to manage costs carefully should factor this into their planning.

Who should consider CagriSema over Wegovy?

CagriSema is not a first-line replacement for Wegovy — it is an escalation option. The clearest candidate is a patient who has plateaued on semaglutide alone and wants the additional amylin mechanism before considering a full medication switch.

CagriSema is not a first-line replacement for Wegovy — it is an escalation option. The patients most likely to benefit are:

Patients who have plateaued on semaglutide alone. If you have been on Wegovy 2.4mg for 6+ months and your weight loss has stalled significantly short of your clinical goals, CagriSema's additional amylin pathway may help break through that plateau. This is the strongest clinical rationale for switching.

Patients who have tried Wegovy HD and want more. If semaglutide 7.2mg produced insufficient additional weight loss, CagriSema offers a mechanistically different approach rather than simply more of the same drug. The ~1-2 percentage point advantage over Wegovy HD is modest, but for some patients those additional pounds are clinically meaningful.

Patients seeking maximum injectable efficacy from Novo Nordisk. CagriSema is Novo Nordisk's most potent injectable obesity treatment. Patients who prefer to stay within the Novo Nordisk ecosystem (due to provider relationships, pharmacy arrangements, or insurance formulary considerations) and want the highest available efficacy may find CagriSema appealing — though they should be aware that tirzepatide (Zepbound) produced superior results in head-to-head data.

Patients with specific GI tolerability concerns. The emerging signal that CagriSema may achieve superior weight loss with a side effect profile that is not proportionally worse than standard-dose semaglutide could matter for patients who are highly sensitive to GI side effects. This remains speculative until confirmed in broader clinical practice.

Who should stick with Wegovy instead of waiting for CagriSema?

Patients doing well on their current Wegovy dose, those who want an oral option, or those managing costs should stay on Wegovy. CagriSema is not available, will cost more, and has no oral formulation.

For many patients, Wegovy remains the better choice — even after CagriSema reaches the market.

Patients responding well to their current Wegovy dose. If you are losing weight steadily on Wegovy 2.4mg or Wegovy HD and tolerating it well, there is no compelling reason to switch. The risk of disrupting a working regimen to chase incremental improvement rarely makes clinical sense.

Patients who want an oral option. CagriSema is injectable only. Oral Wegovy provides a needle-free alternative at a significantly lower cash price ($199-299/month). For patients who dislike injections or lack insurance coverage, oral semaglutide remains a practical advantage that CagriSema cannot match.

Patients who value an established safety track record. Wegovy has been on the market since 2021 and has years of post-marketing safety data, plus the SELECT cardiovascular outcomes trial. CagriSema will launch with clinical trial safety data only. The cagrilintide component is a novel drug without long-term real-world safety data. For risk-averse patients, the known profile of semaglutide alone may provide more comfort.

Patients managing costs. Until CagriSema's pricing, insurance coverage, and savings programs are established, Wegovy offers a clearer financial picture. Oral Wegovy at $199-299/month is particularly attractive for cost-conscious patients.

Patients with injection site sensitivity. If you already experience injection site reactions with Wegovy, the higher rate of injection site reactions with CagriSema (10-15%) would likely make this worse.

Which telehealth providers offer CagriSema or Wegovy?

Wegovy is available through virtually every major telehealth weight loss provider. CagriSema is available from no provider today — it is not FDA-approved. After approval, expect a 2-4 month lag before telehealth access becomes widespread.

Wegovy: Widely Available

Wegovy is offered by virtually every major telehealth weight loss provider, including Hims, Hers, Ro, LifeMD, Found, Calibrate, Sequence, PlushCare, and GoodRx Care. Oral Wegovy is available from an even broader set of providers. Patients have extensive options for telehealth-based prescribing and ongoing management.

CagriSema: Expected Post-Approval

CagriSema is not available from any provider today. After FDA approval, availability will depend on several factors:

• Novo Nordisk partnerships. Providers with existing Novo Nordisk relationships — including Hims, LifeMD, Ro, and GoodRx Care — are most likely to offer CagriSema early, as they already have the pharmacy and distribution infrastructure for Novo Nordisk products.
• Formulary inclusion. Telehealth providers that work with pharmacy benefit managers will need CagriSema added to their formularies before they can prescribe it, which can take 1-3 months post-approval.
• Supply constraints. If Novo Nordisk cannot meet initial demand, some providers may face allocation limits.

Expect a 2-4 month lag between FDA approval and widespread telehealth availability. During this period, access may be limited to patients with commercial insurance through traditional healthcare channels.

What is the bottom line on CagriSema vs Wegovy?

CagriSema is a meaningful advancement over Wegovy for patients who need more weight loss than semaglutide alone can deliver. The ~22% weight loss in REDEFINE-1 represents a genuine step forward from the 15-17% achievable with standard Wegovy. The dual GLP-1 plus amylin mechanism provides a biologically distinct approach to appetite suppression that has now been validated in large clinical trials.

But CagriSema is not available. The FDA decision is pending, pricing is unknown, insurance coverage will take time to establish, and there is no oral option. Wegovy is available today, has a proven cardiovascular benefit from the SELECT trial, costs as little as $0-50/month with insurance, and comes in both injectable and oral formulations.

For patients currently doing well on Wegovy, there is no reason to switch. For patients who have plateaued on semaglutide and are looking for the next option, CagriSema is worth discussing with your provider as it approaches the market — while keeping in mind that tirzepatide (Zepbound) produced superior results in the head-to-head REDEFINE-4 trial and is available right now.

The decision ultimately depends on your individual response to your current medication, your weight loss goals, your insurance situation, and your tolerance for the uncertainty inherent in a medication that has not yet reached pharmacies. Have this conversation with your prescriber, who can evaluate where CagriSema fits in your treatment plan.

Frequently Asked Questions

Is CagriSema better than Wegovy for weight loss? Yes, based on clinical trial data. CagriSema produced ~22% weight loss in REDEFINE-1 versus ~15-17% for standard Wegovy. For a 250-pound patient, that's roughly 12-17 additional pounds. But CagriSema is not yet FDA-approved, and Wegovy is available today.

Should I wait for CagriSema or stay on Wegovy? If you're responding well to Wegovy, stay on it — there's no reason to switch to something that isn't yet available. If you've plateaued on semaglutide and want more weight loss, CagriSema is worth discussing with your provider once it's approved. In the meantime, tirzepatide (Zepbound) is available and produced superior results to CagriSema in REDEFINE-4.

How much will CagriSema cost compared to Wegovy? Wegovy lists at $1,349/month; oral Wegovy costs $199-299/month cash pay. CagriSema pricing has not been announced, but analyst estimates put it at $1,300-1,600/month — more expensive than standard Wegovy, with no oral formulation. Insurance may cover it eventually, but expect limited access in the first months after approval.

Does CagriSema or Wegovy take insurance? Wegovy has broad commercial insurance coverage and qualifies for Medicare's GLP-1 Bridge program. CagriSema has no insurance coverage yet — it's not approved. After approval, coverage typically takes 3-6 months to establish.

What is the main difference between CagriSema and Wegovy? Both contain semaglutide 2.4mg, but CagriSema adds cagrilintide 2.4mg — an amylin analog that suppresses appetite through a second biological pathway. That addition produces roughly 6 more percentage points of weight loss. It also adds injection site reactions that Wegovy users don't experience.

Is CagriSema vs Wegovy even a fair comparison? It's the right framing for patients currently on Wegovy who are considering what comes next. CagriSema is the natural Novo Nordisk upgrade path — same semaglutide backbone, more efficacy. But it's worth knowing that tirzepatide (Zepbound) outperformed CagriSema in head-to-head data, so patients who want maximum injectable efficacy should consider tirzepatide as well.

---

This comparison was last updated on April 2026. CagriSema's FDA status, pricing, and availability will be updated as new information becomes available. For related comparisons, see CagriSema vs Zepbound and CagriSema vs Retatrutide.